{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["33(3)"],"submitter":["Powers TW"],"pubmed_abstract":["The multi-attribute method (MAM), a mass spectrometry technique for quantifying amino acid modifications at the peptide level, is becoming a prominent analytical tool in the development of biotherapeutics. The method has promise for adeno-associated virus (AAV) therapeutics, where capsid protein modifications have been directly linked to reduced transduction efficiency. Given this link, a robust and precise procedure to quantitate capsid modifications would be beneficial for implementation throughout biotherapeutic development. Herein, an AAV product was characterized, and capsid sequence liabilities were identified. A peptide map MAM method was developed to quantitate select sites of modifications and was validated according to ICH Q2(R2). Through this exercise, the method was demonstrate"],"journal":["Molecular therapy. Methods & clinical development"],"pagination":["101560"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12410397"],"repository":["biostudies-literature"],"pubmed_title":["Development and implementation of an LC-MS-based multi-attribute method for adeno-associated virus."],"pmcid":["PMC12410397"],"pubmed_authors":["Mariani S","Powers TW","Narepekha H","Sankar S","Ryan D","Lerch TF"],"additional_accession":[]},"is_claimable":false,"name":"Development and implementation of an LC-MS-based multi-attribute method for adeno-associated virus.","description":"The multi-attribute method (MAM), a mass spectrometry technique for quantifying amino acid modifications at the peptide level, is becoming a prominent analytical tool in the development of biotherapeutics. The method has promise for adeno-associated virus (AAV) therapeutics, where capsid protein modifications have been directly linked to reduced transduction efficiency. Given this link, a robust and precise procedure to quantitate capsid modifications would be beneficial for implementation throughout biotherapeutic development. Herein, an AAV product was characterized, and capsid sequence liabilities were identified. A peptide map MAM method was developed to quantitate select sites of modifications and was validated according to ICH Q2(R2). Through this exercise, the method was demonstrate","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-01T13:59:59.113Z","creation":"2026-04-08T13:14:05.618Z"},"accession":"S-EPMC12410397","cross_references":{"pubmed":["40917693"],"doi":["10.1016/j.omtm.2025.101560"]}}